MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
AtriCure Accounts Receivables 2011-2026 | ATRC
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables AtriCure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.7 M | 60.3 M | 52.5 M | 42.7 M | 33 M | 23.1 M | 28 M | 25.2 M | 23.1 M | 21.1 M | 19.4 M | 17.6 M | 13.7 M | 9.95 M | 9.51 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 66.7 M | 9.51 M | 29.7 M |
Quarterly Accounts Receivables AtriCure
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66 M | 63.3 M | 60.3 M | 54.9 M | 55.6 M | 55.3 M | 52.5 M | 51.5 M | 48.4 M | 45.7 M | 42.7 M | 41.5 M | - | 40.9 M | 33 M | 33.5 M | 33.8 M | 29.7 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 28 M | 28 M | 28 M | 28 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 9.95 M | 9.95 M | 9.95 M | 9.95 M | 9.51 M | 9.51 M | 9.51 M | 9.51 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66 M | 9.51 M | 27.6 M |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M |  USA |
 |
iRhythm Technologies
IRTC
|
75.7 M | $ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Repro Med Systems
KRMD
|
6.21 M | $ 3.96 | -0.75 % | $ 183 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
7.31 M | $ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
829 M | $ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
1.03 M | $ 6.18 | -0.08 % | $ 52.4 K | USA |
 |
ICU Medical
ICUI
|
181 M | $ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Envista Holdings Corporation
NVST
|
430 M | $ 26.8 | -0.89 % | $ 4.5 B | USA |
 |
Isoray
ISR
|
6 K | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
1.53 B | $ 482.22 | 0.71 % | $ 172 B | USA |
 |
Pulse Biosciences
PLSE
|
274 K | $ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
STAAR Surgical Company
STAA
|
50.1 M | $ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
313 K | $ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 10.34 | 0.68 % | $ 214 M | USA |
 |
Stereotaxis
STXS
|
5.85 M | $ 1.93 | -1.53 % | $ 176 M | USA |
 |
Merit Medical Systems
MMSI
|
204 M | $ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Teleflex Incorporated
TFX
|
346 M | $ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
Utah Medical Products
UTMD
|
3.52 M | $ 67.17 | -1.03 % | $ 218 M | USA |
 |
West Pharmaceutical Services
WST
|
574 M | $ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
Retractable Technologies
RVP
|
7.9 M | $ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
33.6 M | $ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
32.1 K | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 21.38 | -1.57 % | $ 985 M | USA |
 |
Baxter International
BAX
|
1.7 B | $ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
576 M | $ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
Harvard Bioscience
HBIO
|
16 M | $ 6.86 | 1.18 % | $ 305 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 11.1 | -0.89 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.99 B | $ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
1.5 M | $ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
OraSure Technologies
OSUR
|
22.2 M | $ 3.0 | -1.64 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 117.6 | 3.1 % | $ 6.55 M | USA |